Plus Therapeutics Inc (PSTV) Stock Price, Quote & News

Company Profile

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid...

Industry: Biotechnology

Sector: Healthcare

Phone: 737 255 7194

Fax: 210 974 6901

Website: plustherapeutics.com

Address:

2710 Reed Road, Suite 160, Houston, United States

Love_To_Learn Jun. 16 at 6:19 PM

$MULN unlocking the 2.75 wormhole belonging to $PSTV for markets and pandora sequence which is coming up

0 · Reply

Love_To_Learn Jun. 16 at 6:06 PM

$CREG metadata transfer $PSTV

0 · Reply

Vulnerable Jun. 16 at 6:04 PM

$PSTV look at that total control listed by mo. Now you have 6 tickers just here, just now, on this board to short. Mustard and mayo imminent.

0 · Reply

Love_To_Learn Jun. 16 at 5:59 PM

$AKBA $PSTV accessing FDA portal database

1 · Reply

Love_To_Learn Jun. 16 at 5:59 PM

$CREG removign the 0.33************ $STTO $PSTV

0 · Reply

Love_To_Learn Jun. 16 at 5:56 PM

$PSTV taking u off channel lock u were being controlled in a tight channel lock range now u will move on your own 2 feet for the time being

1 · Reply

Love_To_Learn Jun. 16 at 5:56 PM

$PSTV i have cleared the 2.61* MARC USING $MULN

1 · Reply

Love_To_Learn Jun. 16 at 5:51 PM

$CREG bringing u in to beloved $PSTV will need to use $OVID temo 0.29 wormhole activation

0 · Reply

Love_To_Learn Jun. 16 at 5:41 PM

$PSTV using agmh !

0 · Reply

moneytra1n Jun. 16 at 5:38 PM

$PSTV Ill help translate. Be ready for sub 0.2 coming very soon. After that you will get reverse split and go sub 0.1. Listen up! 🤌👂

0 · Reply

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

May 23, 2025, 4:15 PM EDT - 23 days ago

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

May 14, 2025, 7:30 AM EDT - 4 weeks ago

Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

May 8, 2025, 7:00 AM EDT - 5 weeks ago

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference

Apr 23, 2025, 8:00 AM EDT - 7 weeks ago

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

Apr 15, 2025, 7:30 AM EDT - 2 months ago

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

Mar 27, 2025, 7:42 PM EDT - 2 months ago

Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:05 PM EDT - 2 months ago

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Mar 20, 2025, 7:30 AM EDT - 3 months ago

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

Mar 19, 2025, 7:30 AM EDT - 3 months ago

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

Mar 11, 2025, 11:00 AM EDT - 3 months ago

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

Mar 10, 2025, 7:30 AM EDT - 3 months ago

Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

Mar 7, 2025, 7:30 AM EST - 3 months ago

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

Mar 6, 2025, 7:30 AM EST - 3 months ago

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Mar 5, 2025, 4:01 PM EST - 3 months ago

Plus Therapeutics Announces New Employment Inducement Grants

Mar 4, 2025, 2:06 PM EST - 3 months ago

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds

Feb 26, 2025, 7:30 AM EST - 3 months ago

Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases

Feb 24, 2025, 7:30 AM EST - 4 months ago

Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary

Feb 20, 2025, 7:30 AM EST - 4 months ago

Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

Feb 18, 2025, 7:30 AM EST - 4 months ago

Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

Dec 17, 2024, 7:30 AM EST - 6 months ago

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Dec 4, 2024, 7:30 AM EST - 6 months ago

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Dec 3, 2024, 7:30 AM EST - 6 months ago

Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply

Nov 25, 2024, 7:30 AM EST - 7 months ago

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

Nov 22, 2024, 7:30 AM EST - 7 months ago

Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases

Nov 21, 2024, 7:30 AM EST - 7 months ago

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

Nov 16, 2024, 2:45 PM EST - 7 months ago

Plus Therapeutics, Inc. (PSTV) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 4:15 PM EST - 7 months ago

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 6, 2024, 7:30 AM EST - 7 months ago

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership

Nov 5, 2024, 7:30 AM EST - 7 months ago

Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024

Oct 29, 2024, 7:30 AM EDT - 8 months ago

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas

Oct 1, 2024, 7:30 AM EDT - 9 months ago

Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting

Sep 18, 2024, 7:30 AM EDT - 9 months ago

Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting

Sep 4, 2024, 7:30 AM EDT - 10 months ago

Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 9:55 PM EDT - 10 months ago

Plus Therapeutics, Inc. (PSTV) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:16 PM EDT - 10 months ago

Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 13, 2024, 7:30 AM EDT - 10 months ago

Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference

Aug 12, 2024, 7:30 AM EDT - 11 months ago

Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference

Aug 8, 2024, 7:30 AM EDT - 11 months ago

Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024

Jul 25, 2024, 7:30 AM EDT - 11 months ago

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference

Jul 2, 2024, 7:30 AM EDT - 1 year ago

Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer

Jun 7, 2024, 7:30 AM EDT - 1 year ago

Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT

May 15, 2024, 9:18 PM EDT - 1 year ago

Plus Therapeutics, Inc. (PSTV) Q1 2024 Earnings Call Transcript

May 15, 2024, 4:15 PM EDT - 1 year ago

Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 13, 2024, 7:30 AM EDT - 1 year ago

Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024

May 9, 2024, 11:29 AM EDT - 1 year ago

Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial

May 8, 2024, 5:35 PM EDT - 1 year ago

Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial

May 6, 2024, 7:30 AM EDT - 1 year ago

Plus Therapeutics Announces Private Placement Financing of up to $18 Million

Apr 22, 2024, 7:00 AM EDT - 1 year ago

Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense

Apr 9, 2024, 7:00 AM EDT - 1 year ago

Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D.

Love_To_Learn Jun. 16 at 6:19 PM

$MULN unlocking the 2.75 wormhole belonging to $PSTV for markets and pandora sequence which is coming up

0 · Reply

Love_To_Learn Jun. 16 at 6:06 PM

$CREG metadata transfer $PSTV

0 · Reply

Vulnerable Jun. 16 at 6:04 PM

$PSTV look at that total control listed by mo. Now you have 6 tickers just here, just now, on this board to short. Mustard and mayo imminent.

0 · Reply

Love_To_Learn Jun. 16 at 5:59 PM

$AKBA $PSTV accessing FDA portal database

1 · Reply

Love_To_Learn Jun. 16 at 5:59 PM

$CREG removign the 0.33************ $STTO $PSTV

0 · Reply

Love_To_Learn Jun. 16 at 5:56 PM

$PSTV taking u off channel lock u were being controlled in a tight channel lock range now u will move on your own 2 feet for the time being

1 · Reply

Love_To_Learn Jun. 16 at 5:56 PM

$PSTV i have cleared the 2.61* MARC USING $MULN

1 · Reply

Love_To_Learn Jun. 16 at 5:51 PM

$CREG bringing u in to beloved $PSTV will need to use $OVID temo 0.29 wormhole activation

0 · Reply

Love_To_Learn Jun. 16 at 5:41 PM

$PSTV using agmh !

0 · Reply

moneytra1n Jun. 16 at 5:38 PM

$PSTV Ill help translate. Be ready for sub 0.2 coming very soon. After that you will get reverse split and go sub 0.1. Listen up! 🤌👂

0 · Reply

Love_To_Learn Jun. 16 at 5:24 PM

$PSTV working the kids on CREG! overlap MLGO BNRG however $VERU 0.61*

0 · Reply

Love_To_Learn Jun. 16 at 5:21 PM

$PSTV we r integrating our grid apart of others for the time being due to pandora 50% out for th e1st time we will remove the 2nd half of pandora and take it out of the market not now but soon

0 · Reply

Love_To_Learn Jun. 16 at 5:20 PM

$PSTV need to awaken our 0.12 and 0.15 bottom to add as pieces part of the board mechanics to aid the 0.29* and allow the 0.19* to move correctly. that 0.19 communicates with the upper channel these lower ranges r related to other stocks @ those ramges as we speak and will be related to a pop coming up @ the bottom quite soon

1 · Reply

Vulnerable Jun. 16 at 5:10 PM

$PSTV i don't know about anybody else, but i feel blessed having all the shareholdersspend their time inviting us to dream of higher prices. That shout goes to the recent pumpers down 25%, those ftom the pump to .80 and 2s and especially those holding down 99.9 fover the last years.

1 · Reply

moneytra1n Jun. 16 at 1:41 PM

$PSTV Daily dose of reality. Just about to crash through 0.3. See you sub 0.2 after that. Alot of fake accounts popping up over here. Funny how that happens when this has big drops 🤔 😂

1 · Reply

B52stealth Jun. 16 at 12:59 PM

$PSTV @328i inspired me to share my experience, I hope you all do. To show our gratitude to the bears on this page trying to make us sell. It was a Thursday night, I was walking my dog out in the countryside, the night was full of stars, suddenly I felt a change in the energy around me and my dog started barking, and a UFO just zapped above me and i was surrounded with a cool blue light.. it was all so scary, but suddenly one of the bears on this page jumped and pushed me away from the beam, saving me and my dog, and while this angelic bear was getting sacked up to get probed by the aliens.. he muttered " don't buy pstv " , I thanked him for his sacrifice.. politly declined his final request and kept walking.. with tears in my

0 · Reply

328i Jun. 16 at 12:09 PM

$PSTV I don’t know about anybody else, but I feel blessed having all these non-shareholders spend all their time on this board advising us not to buy the stock. Thank you so much.🤣🤣🤣🤣

1 · Reply

Love_To_Learn Jun. 16 at 11:08 AM

$BATL activated your *2.45 BEUD and *combination beloved and ENVB *2.61 and 2.67 $PSTV $ENVB this mid 2's is preppign a stock to use to hit double digits in general

1 · Reply

Love_To_Learn Jun. 16 at 10:11 AM

$PSTV last message using faas for rendering that 0.61 reverse engineering the mlgo manipulation

0 · Reply

Love_To_Learn Jun. 16 at 10:09 AM

$PSTV used the kids on mlgo to re-trigger and awaken our old 0.61 roll over take note @The_Gambl3r have been shorting many stocks accordingly

1 · Reply

moneytra1n Jun. 16 at 1:55 AM

$PSTV Account below will last a few more days here then will be forced to liquidate. Just another account that will fall into oblivion like the thousands before. Please send me people that at least can talk about the products or timelines!

0 · Reply

328i Jun. 15 at 11:15 PM

$PSTV the good people who are saving us from this terrible stock they don’t own by spending day after day hour after hour 24/7 of their time and not being compensated for us just to save us from losing our money. Keep up the good work. I appreciate it very much knowing that you have my back.🤣🤣🤣🤣🤣

1 · Reply

Market Cap	5.34M
Revenue (ttm)	5.82M
Net Income (ttm)	-12.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-223.02%
Debt to Equity Ratio	0.00

Volume	1,693,235
Avg Vol	6,968,354
Day's Range	N/A - N/A
Shares Out	17.00M
Stochastic %K	5%
Beta	0.64
Analysts	Strong Sell
Price Target	$10.00